Ironwood Pharmaceuticals, Inc. (IRWD) SEC Filings & Earnings Calls

Leadership transition risk; potential disruption to strategy and operations.

“CEO/CFO departure reported; no successor or transition details provided.”

Concentration on LINZESS; apraglutide still in clinical development.

“LINZESS is primary revenue driver; apraglutide Phase 3 confirmatory trial ongoing.”

Concentration on LINZESS Revenue

“We believe revenues from our LINZESS partnership for the U.S. with AbbVie will continue to constitute a significant portion of our total revenue for the foreseeable future.” · word for word

Debt Obligations

“As of June 30, 2026, our debt is comprised of $385.0 million aggregate principal amount outstanding under our Revolving Credit Facility.” · word for word

Potential dilution from equity plan amendment may pressure EPS and stock price.

“Plan Amendment increases the number of shares available for issuance by 10,000,000 shares.”

Debt repayment reduces financial risk and eliminates potential dilution from conversion.

“No conversions were exercised by holders of the 2026 Convertible Notes”

Potential disruption in financial operations and investor confidence due to CFO departure.

“CFO resignation effective May 15, 2026; interim CFO appointed from within.”

Debt maturity risk: $172.5M convertible notes due June 2026; company expects strong Q1 cash flows to support repayment.

“We expect strong first quarter revenue to result in significant operating cash flows in the second quarter of 2026, which will help support repayment of our 2026 convertible notes at maturity in June.” · word for word

Regulatory risk: sNDA for LINZESS in pediatric FC with PDUFA date May 24, 2026; approval could expand market but adds execution risk.

“sNDA for LINZESS treatment of functional constipation in patients 2 to 5 years of age accepted and granted priority review by FDA; PDUFA date set for May 24th.” · word for word

Debt maturity risk

“We have short-term and long-term debt obligations, including convertible notes that mature on June 15, 2026. There is no assurance we will have sufficient liquidity to meet our debt obligations when they become due.” · word for word

Revenue concentration on LINZESS

“We believe revenues from our LINZESS partnership for the U.S. with AbbVie will continue to constitute a significant portion of our total revenue for the foreseeable future.” · word for word

Material Weaknesses in Internal Control Over Financial Reporting

“EY's report on our internal control over financial reporting as of December 31, 2024, contained an adverse opinion, specifically, that we did not maintain effective internal control over financial reporting as of December 31, 2024, due to the effect of certain material weaknesses described in such report.” · word for word

Dependence on LINZESS and Apraglutide Approval

“the risk that apraglutide will not be approved by the FDA or other regulatory agencies; the risk that the commercial and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect” · word for word

Patent Protection and Competition Risk

“the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates, that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents” · word for word

Pricing and Reimbursement Risk

“the risk of uncertainty relating to pricing and reimbursement policies in the U.S., which, if not favorable for our products, could hinder or prevent our products' commercial success” · word for word

Indebtedness Risk

“the risk that our indebtedness could adversely affect our financial condition or restrict our future operations” · word for word

Activist exit risk

“On March 17, 2026, the Sarissa Funds sold 6,725,000 Shares at a weighted average price of $3.0501 per Share in open market transactions” · word for word

Activist exit risk

“On March 17, 2026, the Sarissa Funds sold 6,725,000 Shares at a weighted average price of $3.0501 per Share in open market transactions” · word for word

No material risk; liquidity condition met.

“Liquidity conditions satisfied”

Generic LINZESS entry by March 2029

“We and AbbVie have entered into settlement agreements with all five of these generic drug manufacturers providing for licenses to market their ... generic versions of LINZESS, beginning as early as March 2029” · word for word

IRA price setting reduces LINZESS net price

“The MFP for a 30-day equivalent supply of LINZESS, which will become the new Medicare net price as of January 1, 2027, is set to $136.” · word for word

Apraglutide approval delayed by confirmatory trial

“a confirmatory Phase III clinical trial is needed to seek approval of an NDA for apraglutide” · word for word

LINZESS U.S. net sales declined 6% in FY2025 due to pricing headwinds from Medicare Part D redesign and gross-to-net adjustments.

“LINZESS U.S. net sales were $864.5 million for the full year 2025, a 6% decrease compared to $916.3 million for the full year 2024.”

Total revenue declined 15.7% in FY2025 due to LINZESS pricing headwinds and collaboration revenue adjustments.

“Total revenue $296,151 for FY2025 vs $351,410 for FY2024.”

LINZESS list price cut may impact future pricing power; reliance on single product.

“Effective January 1, 2026, the LINZESS list price has been lowered.” · word for word

Ongoing royalty obligations may pressure margins; litigation settled.

“High single-digit percentage royalty on net sales.”

Drug pricing pressure from IRA; MFP in line with expectations, but future rounds could be more aggressive.

“LINZESS selected for government price setting under IRA; MFP set at $136.”

Debt covenant compliance risk

“enable us to reduce our debt and maintain compliance with debt covenants over the coming quarters” · word for word

Debt maturity risk

“There is no assurance the Company will have sufficient liquidity to meet its debt obligations when they become due.” · word for word

Litigation risk

“Ferring filed a complaint against VectivBio AG, for trade secret misappropriation and correction of patent inventorship and ownership.” · word for word

Pipeline delay risk

“the Company eliminated certain positions supporting apraglutide commercialization efforts, in consideration of delays in development timelines.” · word for word